WHO ICTRP trial
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center…
NL-OMON54567 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON54567 |
|---|---|
| Public title | A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy |
| Scientific title | A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy - ADRIATIC |
| Primary sponsor | Astra Zeneca |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Argentina;Belgium;Canada;China;Czechia;Germany;India;Italy;Japan;Korea (the Republic of);Netherlands;Russian Federation ;Spain;Taiwan (Province of China);Turkey;United States of America ;Viet Nam |
| Conditions | small-cell lung cancer; lung cancer;10038666;small-cell lung cancer; lung cancer |
| Interventions | For the first 600 patients randomised: Durvalumab + Tremelimumab combination therapy: - Durvalumab (1500 mg IV) q4w in combination with tremelimumab (75 mg IV) q4w for up to 4 doses/cycles each, followed by durvalumab 1500 mg q4w… |
| Registration date | Jul 20, 2023 |
| Target size | 20 |
| Secondary IDs | 2018-000867-10;NCT03703297;NL67090.029.18 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: